Todd M Cooper
Overview
Explore the profile of Todd M Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Place A, Karol S, Forlenza C, Cooper T, Fraser C, Cario G, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31630.
PMID: 40062648
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis....
2.
Cuglievan B, Kantarjian H, Rubnitz J, Cooper T, Zwaan C, Pollard J, et al.
Leukemia
. 2024 Aug;
38(10):2073-2084.
PMID: 39179671
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of...
3.
Schafer E, Rushing T, Crews K, Annesley C, Colace S, Kaiser N, et al.
J Natl Cancer Inst
. 2024 Jul;
116(11):1721-1729.
PMID: 38964343
Background: The National Cancer Institute (NCI) issued a 2021 memorandum adopting the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) task force recommendations to broaden clinical...
4.
Leger K, Absalon M, Demissei B, Smith A, Gerbing R, Alonzo T, et al.
Front Cardiovasc Med
. 2024 Jul;
11:1347547.
PMID: 38947228
Introduction: Anthracyclines are effective in treating acute myeloid leukemia (AML) but limited by cardiotoxicity. CPX-351, a liposomal daunorubicin and cytarabine, may provide therapeutic benefit with less cardiotoxicity. Acute changes in...
5.
Tarlock K, Gerbing R, Ries R, Smith J, Leonti A, Huang B, et al.
Blood Adv
. 2024 Jan;
8(9):2094-2103.
PMID: 38295280
We sought to define the cooccurring mutational profile of FLT3-ITD-positive (ITDpos) acute myeloid leukemia (AML) in pediatric and young adult patients and to define the prognostic impact of cooperating mutations....
6.
Juul-Dam K, Shukla N, Cooper T, Cuglievan B, Heidenreich O, Kolb E, et al.
Eur J Med Genet
. 2024 Jan;
66(12):104869.
PMID: 38174649
Despite advances in the clinical management of childhood acute myeloid leukemia (AML) during the last decades, outcome remains fatal in approximately one third of patients. Primary chemoresistance, relapse and acute...
7.
Leger K, Robison N, Narayan H, Smith A, Tsega T, Chung J, et al.
Front Cardiovasc Med
. 2023 Dec;
10:1286241.
PMID: 38107263
Background: Pediatric acute myeloid leukemia (AML) therapy is associated with substantial short- and long-term treatment-related cardiotoxicity mainly due to high-dose anthracycline exposure. Early left ventricular systolic dysfunction (LVSD) compromises anthracycline...
8.
Paolino J, Dimitrov B, Winger B, Sandoval-Perez A, Rangarajan A, Ocasio-Martinez N, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4613-4626.
PMID: 37725576
Purpose: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable...
9.
Cooper T, Alonzo T, Tasian S, Kutny M, Hitzler J, Pollard J, et al.
Pediatr Blood Cancer
. 2023 Jul;
70 Suppl 6:e30584.
PMID: 37480164
During the past decade, the outcomes of pediatric patients with acute myeloid leukemia (AML) have plateaued with 5-year event-free survival (EFS) and overall survival (OS) of approximately 46 and 64%,...
10.
Kucine N, Jessup J, Cooper T, Urbanski R, Kolb E, Resar L
Pediatr Blood Cancer
. 2023 Jul;
70(10):e30559.
PMID: 37455243
No abstract available.